Janus kinase 2

Janus kinase 2
Name	Janus kinase 2
Uniprot	P29350
Organism	Homo sapiens

Janus kinase 2 Janus kinase 2 is a non-receptor tyrosine kinase expressed in hematopoietic and non-hematopoietic tissues. It participates in cytokine receptor signaling cascades initiated by receptors such as Erythropoietin receptor, Thrombopoietin receptor, and Interleukin-6 receptor, and it is implicated in hematopoiesis, immune responses, and oncogenesis. Disruption of its activity by somatic mutation or dysregulated signaling is associated with disorders described by clinicians, researchers, and institutions including World Health Organization, American Society of Hematology, and regulatory agencies such as Food and Drug Administration.

Structure and mechanism

The protein comprises a pseudokinase domain (JH2) and an active tyrosine kinase domain (JH1), flanked by a Src homology region that mediates receptor association for receptors such as Erythropoietin receptor, Growth hormone receptor, and Prolactin receptor. Crystallographic and cryo-EM studies conducted by laboratories at Max Planck Society and Cold Spring Harbor Laboratory revealed a bilobed catalytic site that binds ATP analogs and substrates recognized in studies by Salk Institute and Harvard Medical School. Biochemical assays developed at National Institutes of Health and pharmaceutical companies such as Novartis and Pfizer established that activation involves trans‑phosphorylation between paired kinase domains following receptor dimerization, a mechanism analogous to reactions characterized in work from Cancer Research UK and Dana-Farber Cancer Institute.

Biological function and signaling

JAK2 mediates signal transduction downstream of class I and class II cytokine receptors including complexes documented by teams at Johns Hopkins University, Mayo Clinic, and Karolinska Institutet. Upon ligand binding to receptors like Interleukin-3 receptor and Granulocyte colony-stimulating factor receptor, JAK2 phosphorylates tyrosine residues that recruit SH2 domain–containing effectors such as Signal transducer and activator of transcription 5 and STAT3, initiating transcriptional programs studied at Massachusetts Institute of Technology and University of Cambridge. Crosstalk with pathways explored by investigators at Stanford University and Broad Institute links JAK2 signaling to regulators including PI3K, AKT1, and MAPK3 (ERK1), shaping cell proliferation in contexts examined by researchers at Fred Hutchinson Cancer Center and Memorial Sloan Kettering Cancer Center.

Regulation and post-translational modifications

Regulatory phosphorylation, ubiquitination, and sumoylation modulate kinase activity; sites mapped in proteomic projects from European Bioinformatics Institute and Proteome Research Center influence interaction with suppressors such as Suppressor of cytokine signaling 1 and Protein tyrosine phosphatase, non-receptor type 11. Negative regulation via proteins studied at University of Oxford and Yale School of Medicine includes SOCS family members and phosphatases characterized by teams at University of California, San Francisco and Imperial College London. Chaperone interactions with heat shock proteins described by researchers at University of Pennsylvania and post-translational control by E3 ligases investigated at University of Tokyo further shape proteostasis relevant to projects supported by Wellcome Trust.

Genetic variants and associated diseases

Somatic variants including the valine-to-phenylalanine substitution at codon 617 (V617F) were first reported in patient cohorts analyzed at University of Cambridge and University of Bologna and are recurrent in myeloproliferative neoplasms catalogued by European LeukemiaNet and clinical series from Mayo Clinic. Germline and somatic alterations associate with disorders evaluated by clinicians from Royal College of Physicians and American Society of Hematology, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis described in case series from Cleveland Clinic and MD Anderson Cancer Center. Mutations modulating kinase activity have also been detected in cohorts assembled by Human Genome Project consortia and variant databases curated at National Center for Biotechnology Information.

Clinical significance and therapeutics

Small-molecule inhibitors targeting the ATP-binding site were developed by teams at Incyte, Novartis, and Jakavi-associated groups; clinical trials coordinated through centers like National Cancer Institute and European Medicines Agency established efficacy of inhibitors in JAK2-mutant myeloproliferative disorders. Therapeutics such as JAK inhibitors studied in randomized trials at University of Chicago and Thomas Jefferson University influence symptoms, splenomegaly, and survival metrics monitored by research networks including European Hematology Association. Resistance mechanisms reported by labs at University of Texas MD Anderson Cancer Center and Cold Spring Harbor Laboratory have informed development of next-generation inhibitors and combination regimens trialed at Memorial Sloan Kettering Cancer Center and community practices overseen by American Society of Clinical Oncology. Safety profiles evaluated by Food and Drug Administration and postmarketing surveillance by Centers for Disease Control and Prevention guide use in settings such as cytopenias and thrombotic risk.

Experimental models and research applications

Murine models engineered at institutions such as The Jackson Laboratory and European Molecular Biology Laboratory carrying activating alleles recapitulate features of human myeloproliferative disease and have been used in preclinical studies at Fred Hutchinson Cancer Center and Sanger Institute. Cellular systems including hematopoietic progenitors from repositories at ATCC and induced pluripotent stem cells generated at Gladstone Institutes enable mechanistic dissection by groups at Stanford University and Broad Institute. High-throughput screens and structural programs from Roche and academic consortia including Wellcome Sanger Institute continue to map interactions and identify modulators, while translational research coordinated by European LeukemiaNet and clinical networks at National Institutes of Health advance biomarker-driven trials.

Category:Tyrosine kinases